张海东累计任职时间81天，现任基金资产总规模6.28亿元，任职期间最佳基金回报1.4%， 任职期间最 差基金回报-3.77%。 从基金十大重仓股角度 数据显示，金元顺安基金旗下1只基金重仓迪哲医药。金元顺安医疗健康混合A类（007861）三季度持 有股数3.52万股，与上期相比持股数量不变，占基金净值比例为4.26%，位居第七大重仓股。根据测 算，今日浮盈赚取约11.25万元。 金元顺安医疗健康混合A类（007861）成立日期2021年7月29日，最新规模3836.83万。今年以来收益 11.56%，同类排名5689/8145；近一年收益0.37%，同类排名7675/8059；成立以来亏损54.15%。 11月13日，迪哲医药涨5.19%，截至发稿，报64.86元/股，成交8596.39万元，换手率0.30%，总市值 299.13亿元。 资料显示，迪哲(江苏)医药股份有限公司位于江苏省无锡市新吴区和风路26号汇融商务广场C栋404、 405、416室,中国(上海)自由贸易试验区亮景路199、245号4幢，成立日期2017年10月27日，上市日期 2021年12月10日，公司主营业务涉及创新药物的研发和产业化, ...

11月12日，迪哲医药涨3.44%，成交额2.55亿元。两融数据显示，当日迪哲医药获融资买入额1446.18万 元，融资偿还1553.61万元，融资净买入-107.43万元。截至11月12日，迪哲医药融资融券余额合计1.65 亿元。 资料显示，迪哲(江苏)医药股份有限公司位于江苏省无锡市新吴区和风路26号汇融商务广场C栋404、 405、416室,中国(上海)自由贸易试验区亮景路199、245号4幢，成立日期2017年10月27日，上市日期 2021年12月10日，公司主营业务涉及创新药物的研发和产业化,高度重视员工的创新研发能力。主营业 务收入构成为：销售药品100.00%。 截至9月30日，迪哲医药股东户数8806.00，较上期增加5.01%；人均流通股46528股，较上期增加 108.97%。2025年1月-9月，迪哲医药实现营业收入5.86亿元，同比增长73.23%；归母净利润-5.80亿元， 同比减少3.85%。 机构持仓方面，截止2025年9月30日，迪哲医药十大流通股东中，永赢医药创新智选混合发起A （015915）位居第四大流通股东，持股591.09万股，相比上期增加229.51万股。香港中央 ...

资料显示，迪哲(江苏)医药股份有限公司位于江苏省无锡市新吴区和风路26号汇融商务广场C栋404、 405、416室,中国(上海)自由贸易试验区亮景路199、245号4幢，成立日期2017年10月27日，上市日期 2021年12月10日，公司主营业务涉及创新药物的研发和产业化,高度重视员工的创新研发能力。主营业 务收入构成为：销售药品100.00%。 截至9月30日，迪哲医药股东户数8806.00，较上期增加5.01%；人均流通股46528股，较上期增加 108.97%。2025年1月-9月，迪哲医药实现营业收入5.86亿元，同比增长73.23%；归母净利润-5.80亿元， 同比减少3.85%。 机构持仓方面，截止2025年9月30日，迪哲医药十大流通股东中，永赢医药创新智选混合发起A （015915）位居第四大流通股东，持股591.09万股，相比上期增加229.51万股。香港中央结算有限公司 位居第六大流通股东，持股450.66万股，为新进股东。东方红医疗升级股票发起A（015052）位居第八 大流通股东，持股339.07万股，相比上期增加127.37万股。鹏华医药科技股票A（001230）位居第九大 流通股 ...

中新网北京11月10日电(记者 张尼)近期，上市公司三季报陆续披露，多家创新药企业交出亮眼"成绩 单"。在政策红利、资本助力与临床需求的三重驱动下，行业正经历从"研发投入期"向"商业化收获 期"的关键转型。 创新药企业交亮眼三季报 11月6日，今年市值大涨的百济神州发布了2025年三季报。 第三季度，百济神州营收超过100亿元，同比增长41.1%，其中产品收入实现99.54亿元，同比增长 40.6%。前三季度整体来看，百济神州营收达275.95亿元，同比增长44.2%，已超过去年全年营收272.1 亿元，其中前三季度产品收入为273.14亿元，同比增长43.9%。 其他创新药头部企业表现亦亮眼。 更早之前的10月27日，恒瑞医药发布2025年三季报，今年前三季度，公司实现营业收入231.88亿元，同 比增长14.85%；归属于上市公司股东的净利润57.51亿元，同比增长24.50%。 药明康德披露的三季报显示，前三季度实现营业收入328.57亿元，同比增长18.61%；归属于上市公司股 东的净利润120.76亿元，同比增幅达到84.84%。 君实生物前三季度实现营业收入18.06亿元，同比增长42.06%；归 ...

证券代码：688192 证券简称：迪哲医药 公告编号：2025-58 迪哲（江苏）医药股份有限公司 2022 年限制性股票激励计划首次授予部分第一类激励 对象第二个归属期归属结果暨股票上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上 市股数为1,775,000股。 本次股票上市流通总数为1,775,000股。 1. 2022 年 11 月 25 日，公司召开第一届董事会第十二次会议，审议通过了《关 于<公司 2022 年限制性股票激励计划（草案）>及其摘要的议案》《关于<公司 2022 年限制性股票激励计划实施考核管理办法>的议案》《关于 2022 年限制性股票激励 计划拟激励对象获授股份数量累计超过公司总股本 1%的议案》及《关于提请股东 大会授权董事会办理公司限制性股票激励计划相关事宜的议案》。公司独立董事就 本次激励计划相关议案发表了独立意见。具体内容详见公司于 2022 年 11 月 28 日 1 在上海证券交易所网站（www.sse. ...

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology industry [1]. Core Views - The report highlights a positive change in the specialty raw materials sector, recommending companies such as Aorite and Prolo Pharmaceuticals [1]. - The report suggests that the Q3 performance of raw material pharmaceutical companies has reached a bottom, indicating potential recovery in profitability as high-cost inventory is consumed [19][20]. Summary by Sections Investment Highlights - The recommended sub-industry rankings are: Innovative Drugs > Research Services > CXO > Traditional Chinese Medicine > Medical Devices > Pharmacies [3][12]. - Specific stock recommendations include: - From raw materials: Aorite, Qianhong Pharmaceutical - From Traditional Chinese Medicine: Zorui Pharmaceutical, Fangsheng Pharmaceutical, Dong'e Ejiao - From medical devices: United Imaging Healthcare, Yuyue Medical - From AI pharmaceuticals: Jingtai Holdings - From GLP-1 sector: Lianbang Pharmaceutical, Borui Pharmaceutical, Zhongsheng Pharmaceutical, and Innovent Biologics - From PD-1/VEGF dual antibodies: Sanofi Biopharmaceuticals, Kangfang Biologics, and Rongchang Biopharmaceuticals - From innovative drugs: Innovent Biologics, BeiGene, HengRui Medicine, Zai Lab, Baillie Tianheng, Kelun Pharmaceutical, Dize Pharmaceutical, and Haizheng Pharmaceutical [3][15]. Industry Trends - The A-share pharmaceutical index has seen a year-to-date increase of 18.2%, while the Hang Seng Biotechnology Index has increased by 76.6% [6][11]. - The report notes that the raw material pharmaceutical sector is under pressure due to high base effects and declining prices, with significant revenue impacts [19][20]. R&D Progress and Company Dynamics - Recent approvals include Novartis' radioligand therapy drug, which received dual indications for prostate cancer treatment [2]. - The report provides an overview of ongoing clinical trials and drug approvals, emphasizing the importance of innovation in the pharmaceutical sector [30]. Market Performance - The report indicates that the pharmaceutical sector has experienced adjustments, with notable stock performances including significant gains for companies like Hezhong China (+61%) and Wanze Shares (+30%) [11]. - The report also highlights the performance of various pharmaceutical stocks, noting both gains and losses in the market [16][17]. Raw Material Pricing Trends - The price of 6-APA has dropped significantly, from 370 RMB/kg in 2022 to 180 RMB/kg in October 2025, a decrease of 51% [23]. - The price of Amoxicillin has also decreased from 320 RMB/kg in January 2023 to 190 RMB/kg in October 2025, a decline of 41% [23]. Conclusion - The report suggests that as high-cost inventory is depleted, the gross margins for raw material producers are expected to improve, indicating a potential recovery in profitability for companies like Fuxiang Pharmaceutical and Lukang Pharmaceutical [19][23].

Core Viewpoint - Dize Pharmaceutical (688192) has experienced a decline in stock price, closing at 59.77 yuan, down 6.17% from the previous week, with a current market capitalization of 27.459 billion yuan, ranking 15th in the chemical pharmaceutical sector and 692nd in the A-share market [1] Group 1: Company Performance - For the first three quarters of 2025, the company achieved revenue of 586 million yuan, representing a year-on-year growth of 73% [5] - The company's core products, Shuwozhe (舒沃哲) and Gao Ruizhe (高瑞哲), have been successfully included in the national medical insurance directory, maintaining rapid growth post-inclusion [5][6] - The company is currently in a loss-making state but aims to expedite the launch of more products or indications to achieve profitability sooner [3] Group 2: Product Development and Market Position - Shuwozhe is the first and only domestically developed innovative drug approved in the U.S. for EGFR Exon20ins NSCLC, and it has been included in the NCCN guidelines for non-small cell lung cancer [4] - Gao Ruizhe is the first drug targeting the JAK/STAT pathway for peripheral T-cell lymphoma (PTCL), showing significant clinical benefits and the longest median overall survival (mOS) among single-agent treatments for relapsed/refractory PTCL [4] - The company has established a competitive clinical product pipeline with seven products, including Shuwozhe and Gao Ruizhe, which are expected to enhance the company's international standing in the innovative drug industry [4] Group 3: Research and Development Initiatives - The global registration clinical study "JCKPOT8 B part" for Gao Ruizhe has reached its primary research endpoint, and the company is actively validating the new drug application for overseas markets [3] - Birelentinib (DZD8586) has initiated a Phase III clinical study for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with active participant recruitment [3] - The company is assessing various overseas collaboration models for Shuwozhe, focusing on global commercialization capabilities and pipeline synergy [2]

Core Viewpoint - The Chinese innovative drug market is entering a rapid development phase, with local leading companies like Heng Rui benefiting from policy support and industry expansion opportunities [1] Company Performance - Heng Rui Pharmaceutical reported a revenue of 23.188 billion yuan for the first three quarters of 2025, a year-on-year increase of 14.85%, and a net profit of 5.751 billion yuan, up 24.50% [2] - The company has received a total cash dividend of over 9.3 billion yuan, enhancing investor returns [1] - The company has established a differentiated competitive advantage through over 50 billion yuan in R&D investment and has 24 innovative drugs approved for sale in China [1] Industry Trends - The innovative drug sector is experiencing accelerated commercialization and increased business development (BD) transactions, leading to a sustained trend of rapid growth in performance [1] - Other innovative drug companies, such as Zai Lab and DiZhe Pharmaceutical, are also reporting significant revenue growth, with Zai Lab achieving a 54.49% increase in revenue to 593 million yuan [3] - The industry is expected to continue its growth trajectory, supported by favorable national policies and increasing international collaboration [4][5] R&D Focus - Heng Rui's innovative drugs, including Rivoceranib and Darsylis, are addressing unmet clinical needs, contributing to their revenue growth [2] - Zai Lab emphasizes its differentiated product pipeline focusing on oncology and autoimmune diseases, aiming to fill domestic gaps in treatment options [3] - The industry is witnessing a rise in R&D investments, with companies like Yi Fang Bio reporting a total R&D investment of 190 million yuan for the first three quarters of 2025 [4] Future Outlook - Analysts predict a new round of growth for the pharmaceutical sector, particularly in innovative drugs, as the international standing of Chinese innovative drug companies rises [5] - The innovative drug sector is expected to remain a key investment theme in the pharmaceutical industry through 2026, driven by increased BD transactions and international collaborations [5]

Core Viewpoint - Dize Pharmaceutical's stock performance and financial metrics indicate a mixed outlook, with significant revenue growth but ongoing net losses, reflecting challenges in profitability despite strong sales growth [1][2]. Group 1: Stock Performance - On November 5, Dize Pharmaceutical's stock price remained unchanged at 0.00%, with a trading volume of 234 million yuan [1]. - The financing buy-in amount for Dize Pharmaceutical on the same day was 9.97 million yuan, while the financing repayment was 12.63 million yuan, resulting in a net financing outflow of 2.66 million yuan [1]. - As of November 5, the total balance of margin trading for Dize Pharmaceutical was 166 million yuan, which accounts for 0.58% of its market capitalization [1]. Group 2: Financial Performance - For the period from January to September 2025, Dize Pharmaceutical reported a revenue of 586 million yuan, representing a year-on-year growth of 73.23% [2]. - The company's net profit attributable to shareholders was -580 million yuan, showing a year-on-year decrease of 3.85% [2]. - As of September 30, 2025, the number of shareholders increased to 8,806, up by 5.01%, with an average of 46,528 circulating shares per person, an increase of 108.97% [2]. Group 3: Shareholder Composition - As of September 30, 2025, the fourth largest circulating shareholder was Yongying Pharmaceutical Innovation Mixed Fund A, holding 5.91 million shares, an increase of 2.30 million shares from the previous period [2]. - Hong Kong Central Clearing Limited entered as a new sixth largest shareholder with 4.51 million shares [2]. - Other notable changes include an increase in holdings by Dongfanghong Medical Upgrade Fund A and a decrease by Penghua Pharmaceutical Technology Fund A among the top ten circulating shareholders [2].

Core Insights - A total of 77 stocks in the Shanghai and Shenzhen markets have experienced net inflows of main funds for five consecutive days or more as of November 5, with Cambricon Technologies (寒武纪-U) leading with 50 days of continuous inflow [1] - The total net inflow of main funds for Cambricon Technologies reached 6.325 billion yuan, followed by Shanghai Pudong Development Bank with a net inflow of 777 million yuan over five days [1] - In terms of the proportion of net inflow to trading volume, *ST Baoying ranks first, with a 47.72% increase over the past eight days [1] Summary by Category Stocks with Continuous Net Inflows - Cambricon Technologies (688256) has seen net inflows for 50 days totaling 6.325 billion yuan, with a price increase of 44.33% [1] - Shanghai Pudong Development Bank (600000) recorded net inflows of 777 million yuan over five days, with a price increase of 0.42% [1] - CITIC Bank (601998) had net inflows of 439 million yuan over six days, with a price increase of 3.85% [1] Notable Performers - *ST Baoying had the highest net inflow ratio, with a significant price increase of 47.72% over the last eight days [1] - Other notable stocks include Jiangsu Bank (600919) with a net inflow of 342 million yuan and a price increase of 5.70%, and Yaxing Anchor Chain (601890) with a net inflow of 331 million yuan and a price increase of 10.16% [1] Additional Stocks with Inflows - Other stocks with notable net inflows include: - China Shenhua (601088) with 314 million yuan and a 3.42% increase [1] - Haotian Co., Ltd. (603759) with 166 million yuan and a 64.35% increase over 11 days [1] - Microelectronic Physiology (688351) with 140 million yuan and a 12.94% increase [1]